Overview

  • Product name
    NVP-BEZ235
  • Description
    Potent PI3K and mTOR inhibitor
  • Alternative names
    • BEZ-235
    • BEZ235
    • Dactolisib
  • Biological description

    Potent, ATP-competitive Phosphatidylinositol 3-kinase (PI3K) inhibitor (IC50 = 4, 5, 7 and 75 nM for PI3Kα, -γ, -δ, and -β respectively) and mTOR inhibitor. Able to directly induce G1 arrest and inhibit angiogenesis in vitro and potentiate the efficacy of other anticancer agents in vivo.

  • Purity
    > 98%

Properties

References

This product has been referenced in:
  • Moon du G  et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells. Int J Oncol 45:1027-35 (2014). Read more (PubMed: 24969552) »
  • Roper J  et al. The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer. PLoS One 6:e25132 (2011). Read more (PubMed: 21966435) »
  • Maira SM  et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7:1851-63 (2008). Read more (PubMed: 18606717) »
  • Serra V  et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 68:8022-30 (2008). Read more (PubMed: 18829560) »

See 0 Publications for this product

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab120882.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE, NOT FOR USE IN HUMANS"

Sign up